The central problem the researchers set out to solve is antigen loss. CD19-directed CAR-T cells work by recognizing the CD19 protein on the surface of malignant B cells, but leukemia cells can survive the assault by reducing or eliminating that surface target. When CD19 disappears from the cell membrane, the engineered T cells have nothing to lock onto, and the tumor slips through. This phenomenon of antigen escape is a well-documented cause of relapse after CAR-T treatment, and it is particularly troublesome in CLL, where response rates have lagged behind those seen in acute lymphoblastic leukemia and large B cell lymphoma. Understanding why CLL cells shed their CD19 so readily has therefore become a major focus of laboratory investigation.

The research team, led by investigators at Fujian Medical University Union Hospital and Ruijin Hospital of Shanghai Jiao Tong University School of Medicine, focused on NOTCH1, a signaling receptor with a complicated reputation in leukemia biology. NOTCH1 mutations are common in CLL and influence how the disease progresses, but the pathway’s role in shaping the tumor’s vulnerability to immunotherapy had not been clearly defined. Using the MEC-1 cell line, a widely used model of CLL, the scientists manipulated NOTCH1 signaling in two complementary ways: genetically, by knocking out the gene, and pharmacologically, by treating the cells with inhibitors. They then measured how these altered leukemia cells fared when confronted with CD19-targeted CAR-T cells in laboratory assays.

The results were unambiguous. Leukemia cells lacking functional NOTCH1 signaling were killed far more effectively by the CAR-T cells than their unmodified counterparts. The difference was not a subtle shift in a culture dish; it represented a profound enhancement of the engineered cells’ killing potency. The team traced the effect to a surprising mechanism: rather than NOTCH1 controlling how much CD19 the leukemia cells produce, it controlled how quickly the cells destroyed the CD19 they had already made.

Here is where the cellular machinery gets intricate. When a CAR-T cell engages a leukemia cell through the CD19 receptor, the leukemia cell responds by pulling CD19 off its surface and shuttling it into internal compartments. Inside the cell, the captured protein is routed to lysosomes, the acidic organelles that function as cellular garbage disposals, where it is degraded. The study showed that NOTCH1 signaling actively promotes this disposal process. In other words, the very act of being attacked triggers the leukemia cell to destroy the molecular flag that the immune cells are aiming at, a form of triggered antigen loss that unfolds rapidly enough to blunt the immune response.

The molecular pathway behind this behavior runs through a transcriptional regulator called HEY1, one of the canonical downstream effectors of NOTCH signaling. When NOTCH1 is active, HEY1 is produced and represses the transcription of a gene called RAB31. RAB31 encodes a small GTPase protein that normally acts as a brake on RAB7, a transporter that governs traffic between late endosomes and lysosomes. With RAB31 suppressed, the RAB7-mediated transport route runs unchecked, and internalized CD19 is efficiently delivered to the lysosome for destruction. The researchers demonstrated that this NOTCH1–HEY1–RAB31–RAB7 axis is essential for the rapid loss of surface CD19 after CAR-T engagement. When any link in that chain is broken, the degradation stalls and CD19 accumulates on the cell surface.

The practical consequences of interrupting this pathway were consistent across the team’s experiments. Both NOTCH1-deficient leukemia cells and cells treated with pharmacological NOTCH inhibitors showed impaired CD19 degradation and higher retention of the antigen on their membranes. That surface retention translated directly into greater susceptibility to CAR-T cell killing. The engineered T cells, presented with more abundant CD19 targets, became more activated, and the researchers measured elevated secretion of effector molecules, the inflammatory proteins such as cytokines and cytotoxic factors that CAR-T cells release when they recognize and attack their targets. The combination of NOTCH1 inhibition and CD19 CAR-T therapy thus produced a stronger immune attack than either approach alone.

Importantly, the team did not confine their findings to laboratory dishes. They evaluated the combination strategy in vivo, using animal models of CLL, and the results supported the mechanistic work: pairing NOTCH1 pathway inhibition with CD19 CAR-T cells enhanced therapeutic efficacy in living systems. The animal study was conducted under institutional ethical approval, and the work was funded by the National Natural Science Foundation of China and several Fujian provincial research programs, reflecting a sustained institutional investment in translational hematology research.

The implications for clinical practice are considerable, though they come with caveats. NOTCH inhibitors exist and have been tested in humans for other indications, which means that a combination regimen of NOTCH blockade followed or accompanied by CD19 CAR-T infusion is a plausible near-term clinical strategy rather than a distant theoretical possibility. If the laboratory findings translate to patients, pretreating CLL with a NOTCH pathway inhibitor could preserve surface CD19 long enough for infused CAR-T cells to achieve deeper and more durable responses, potentially addressing one of the main reasons the therapy underperforms in this disease. The approach also illustrates a broader principle that is reshaping cancer immunotherapy research: the tumor’s own signaling circuits can be rewired to make it a better target, turning resistance mechanisms into therapeutic vulnerabilities.

At the same time, the researchers and the field more broadly will need to navigate real challenges before this combination reaches the clinic. NOTCH signaling plays important roles in normal T cell development and intestinal stem cell maintenance, so systemic inhibition carries known toxicities that must be managed carefully, particularly in patients about to receive engineered T cells whose function depends on healthy immune biology. The current study relied on the MEC-1 cell line and animal models, and primary CLL cells from patients show considerable biological heterogeneity, including variable NOTCH1 mutation status, that could modulate the strategy’s effectiveness. Dosing, sequencing, and timing of the combination will all require careful optimization. Nevertheless, by dissecting the precise chain of molecular events that lets leukemia cells discard their CD19 target under fire, the study offers both a mechanistic explanation for CAR-T resistance in CLL and a concrete, druggable intervention point. It transforms a frustrating clinical problem into a defined biological pathway, and it suggests that the next generation of CAR-T therapy for chronic lymphocytic leukemia may succeed not by building a better T cell, but by first disarming the tumor’s escape route.

Subject of Research: NOTCH1 regulation of CD19 antigen degradation and its impact on CD19 CAR-T cell therapy efficacy in chronic lymphocytic leukemia

Article Title: Targeting the NOTCH1 signaling pathway in chronic lymphocytic leukemia enhances the efficacy of CD19 CAR-T cells

Article References: Zheng, H., Xian, H., Lu, C., Zhang, W., Wang, Y., Wang, M., Lin, S., Chen, S., Huang, Z., Yu, Y., Zheng, Y., Bai, Y., Liu, H., & Xu, Z. (2026). Targeting the NOTCH1 signaling pathway in chronic lymphocytic leukemia enhances the efficacy of CD19 CAR-T cells. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04584-9

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04584-9

Keywords: chronic lymphocytic leukemia, CAR-T cell therapy, CD19, NOTCH1 signaling pathway, antigen loss, HEY1, RAB31, RAB7, lysosomal degradation, immunotherapy resistance, MEC-1, hematology